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 Fatty acids are a major energy source for skeletal muscle. 
They are transported into the cell via a protein-mediated 
mechanism, involving fatty acid translocase/CD36 (FAT/
CD36), plasma-membrane-associated fatty acid binding 
protein, and fatty acid transport protein (FATP1-6) ( 1 ). 
Once inside the cell, fatty acids can be esterifi ed, metabo-
lized to lipid second messengers, such as leukotrienes and 
eicosanoids, or   -oxidized in the mitochondrion. The fi rst 
step of the oxidative pathway is the transport of fatty acids 
into the mitochondrial matrix. This step is controlled by 
the carnitine palmitoyltransferase (CPT) system, consist-
ing of CPT1, acylcarnitine translocase, and CPT2 ( 2 ). 
 CPT1 catalyzes the conversion of long-chain fatty acyl-
CoAs to acylcarnitines in the presence of  L -carnitine and is 
the rate-limiting step in the transport of long-chain fatty 
acids (LCFAs) from the cytoplasm to the mitochondrial 
matrix, where they undergo   -oxidation. CPT1 is tightly 
regulated by its physiological inhibitor malonyl-CoA. This 
regulation allows CPT1 to signal the availability of lipid 
and carbohydrate fuels to the cell ( 2 ). Mammalian tissues 
express three isoforms: CPT1A (liver), CPT1B (muscle 
and heart), and CPT1C (brain) ( 3–5 ). 
 Owing to the metabolic peculiarities of muscle, the regula-
tion of CPT1B by malonyl-CoA is more complex than that 
of CPT1A in liver. The regulation of muscle CPT1 by malonyl-
 CoA cannot fully explain changes in mitochondrial fatty 
acid import. Thus, malonyl-CoA is not responsible for the 
increase in fatty acid oxidation during the transition from 
low to moderate aerobic exercise or for the decrease in fatty 
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 EXPERIMENTAL PROCEDURES 
 Materials and reagents 
 Protran® nitrocellulose membranes for protein analysis were 
from Scheicher and Schuell (Keene, NH). The enhanced chemi-
fl uorescence detection kit from Amersham Biosciences was used 
for Western blot analysis. The Bradford solution for protein assay 
was from Bio-Rad Laboratories (Hercules, CA). FBS, DMEM, and 
antibiotics were from Gibco-Invitrogen. Defatted BSA (BSA), 
palmitate, and other chemicals were purchased from Sigma-
Aldrich. [1- 14 C]Palmitic acid and [1- 14 C]palmitoyl-CoA were from 
GE Healthcare. Antibodies used included rabbit polyclonal anti-
FATP1 (sc-14497) and rabbit polyclonal anti-FAT/CD36 (sc-
9154) from Santa Cruz Biotechnologies, anti-green fl uorescent 
protein (GFP) (ref. 8360-1) from Clontech, anti-COI of complex 
IV from Molecular Probes, and anti-porin from Calbiochem. Sil-
ica gel 60 TLC plates were from Merck (Rahway, NJ). Etomoxir 
was provided by H. P. O. Wolf (GMBH, Allensbach, Germany). 
 Animals 
 Samples of gastrocnemius and soleus muscle were taken from 
male Sprague-Dawley rats (180–200 g) bred in our laboratory. 
Animals were maintained under a 12 h dark/light cycle at 23°C 
with free access to food and water. All experimental protocols 
were approved by the Animal Ethics Committee at the University 
of Barcelona. 
 Cell culture 
 The L6E9 rat skeletal muscle cell line was cultured in a hu-
midifi ed atmosphere containing 5% CO 2 in DMEM medium con-
taining 10% FBS, 100 units/ml penicillin G, and 100   g/ml 
streptomycin and 25 mmol/l  HEPES (pH 7.4) (growth medium). 
Preconfl uent myoblasts (80–90%) were induced to differentiate 
by lowering FBS to a fi nal concentration of 2% (v/v) (differentia-
tion medium). Cells were completely differentiated after 4 days 
in this medium. 
 Adenoviral preparation and transduction of L6E9 cells 
 Ad-CPT1A encoding rat CPT1A, Ad-FATP1 encoding mouse 
FATP1, Ad-FAT/CD36 encoding rat FAT/CD36, and Ad-LacZ, 
which expresses bacterial   -galactosidase, were constructed as 
previously described ( 18, 23 ). Adenoviruses were amplifi ed using 
the human embryonic kidney cell line (HEK 293) as host. Lysates 
obtained were titrated using the Adeno-X TM Rapid Titer kit 
(Clontech) and used directly for cell transduction. The titers of 
the lysates were 2.3 × 10 9 pfu/ml for Ad-LacZ, 1 × 10 10 pfu/ml for 
Ad-CPT1A, 1 × 10 10 pfu/ml for Ad-FAT/CD36, and 3 × 10 10 pfu/
ml for Ad-FATP1. Myotubes were transduced at day 4 of differen-
tiation with 20 pfu/cell of Ad-LacZ, Ad-FATP1, or Ad-CPT1A and 
5 pfu/cell of Ad-FAT/CD36 in serum-free medium for 30 h. Af-
ter this time, the infection medium was removed and cells were 
incubated with serum-free medium for a further 16 h. 
 Transfection of L6E9 cells 
 The plasmids pFATP1-GFP and pFAT/CD36-GFP, which in-
clude an NH 2 -terminal fusion protein construct with the GFP 
( 20 ), were transfected in L6E9 myoblasts using FuGENE 6 
(Roche) following the manufacturer’s guidelines. After transfec-
tion, cells were differentiated and used for the experiments. 
 Measurement of fatty acid oxidation in intact cells 
 Palmitate oxidation to CO 2 and acid-soluble products (ASPs), 
essentially acyl-carnitine, Krebs cycle intermediates, and acetyl-
CoA ( 24 ), were measured in L6E9 cells grown in 6-well plates, 
differentiated, and transduced as described above. On the day of 
acid oxidation during more strenuous exercise ( 6–8 ). More-
over, concentrations of malonyl-CoA measured in muscle 
(1–4 µM) ( 9, 10 ) should inhibit CPT1 activity at any time, 
since the IC 50 of CPT1B for malonyl-CoA is much lower 
than this concentration (  0.03 µM). Several hypotheses 
have been advanced to explain this discordance between 
malonyl-CoA levels, CPT1 regulation, and LCFA oxidation 
in muscle. Thus, alteration in compartmentalization/cellu-
lar distribution of malonyl-CoA may be involved in the 
control of CPT1 activity. It has been proposed that the 
malonyl-CoA involved in CPT1 regulation is that synthesized 
by acetyl-CoA carboxylase 2, which resides in the vicinity 
of CPT1 in the outer mitochondrial membrane and modu-
lates CPT1 activity ( 11 ). Moreover, other proteins could 
also be involved in the transport of fatty acids into mito-
chondria. Thus, Bonen and coworkers demonstrated that 
exercise induces the translocation of FAT/CD36 to mito-
chondria, thus increasing muscle fatty acid oxidation ( 12 ). 
 FATPs are a family of membrane-bound proteins that 
catalyze the ATP-dependent esterifi cation of LCFA and 
very-LCFA to their acyl-CoA derivatives ( 13–15 ). Mammals 
express six different forms of FATP (FATP1-6) with tissue-
specifi c expression patterns ( 14 ). FATP1 is a 63 kDa protein 
that is expressed in cells and tissues with high levels of fatty 
acid uptake for metabolism or storage, such as skeletal mus-
cle and adipose tissue ( 15 ). The regulatory role of FATP1 in 
metabolism has been partially elucidated by gene manipu-
lation. Overexpression of FATP1 in cultured fi broblasts in-
creases fatty acid uptake ( 16 ). Cardiac-specifi c overexpression 
of FATP1 in transgenic mice increases myocardial fatty acid 
uptake and free FA accumulation, but not triacylglyceride 
(TG) levels, and enhances palmitate oxidation leading to 
a lipotoxic cardiomyopathy ( 17 ). In contrast, when overex-
pressed in cultured human skeletal myotubes, FATP1 stim-
ulates FA uptake and storage as TG, but not oxidation ( 18 ). 
Deletion of FATP1 protects mice from fatty-acid-induced 
insulin resistance and intramuscular accumulation of fatty 
acyl-CoAs ( 19 ). Furthermore, FATP1 is involved in hor-
monal regulation of fatty acid uptake, translocating to the 
plasma membrane in response to insulin in adipocytes and 
primary skeletal muscle cells ( 20, 21 ). 
 We have recently shown that overexpression of CPT1A 
in L6E9 myotubes enhanced CPT1 activity up to 15-fold, 
whereas fatty acid oxidation did not increase more than 
2-fold, even when a mutant form of CPT1 insensitive to 
malonyl-CoA was overexpressed ( 22 ). These data indicate 
that other factors independent of CPT1/malonyl-CoA in-
teraction could be involved in the control of fatty acid oxi-
dation in these cells. In the search for a novel regulator 
of fatty acid oxidation in skeletal muscle, we examined the 
effect of FATP1 overexpression on fatty acid oxidation in 
L6E9 muscle cells. We show that FATP1 localized in mito-
chondria and coimmunoprecipitated with CPT1. Moreover, 
FATP1 overexpression enhanced mitochondrial oxidation 
of fatty acids. We also observed all these effects in cells 
overexpressing FAT/CD36, which may have a role in this 
process in muscle ( 12 ). These data reveal a new protein 
involved in   -oxidation and could help us to understand 
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parafi lm-sealed system in a 6-well plate with agitation. The reac-
tion was stopped by the addition of 40% perchloric acid through 
a syringe that pierced the parafi lm. 
 Measurement of palmitate incorporation into 
cellular lipids 
 Palmitate incorporation into complex lipids was measured in 
L6E9 cells that were cultured on 6-well plates and pretreated as 
described above. Cells were incubated for 16 h at 37°C in serum-
free medium containing 0.25 mM palmitate and 1   Ci/ml [1- 14 C]
palmitate bound to 1% BSA. On the day of the assay cells were 
washed in PBS, and lipids were extracted as described previously 
( 23 ). Total lipids were dissolved in 30   l of chloroform and sepa-
rated by TLC to measure the incorporation of labeled fatty acid 
into phospholipids (PLs), diacylglycerol (DAG), TGs, and nones-
terifi ed labeled palmitate (NE palm), as described ( 22 ). 
 Measurement of acyl-CoA synthetase activity 
 Samples were assayed for acyl-CoA synthetase activity by the 
conversion of [1- 14 C]palmitate to its CoA derivative ( 13 ). The as-
say mixture contained, in a total volume of 200 µl: 100 mM Tris-
HCl buffer, pH 7.5, 50 µM [1- 14 C]palmitate (0.2 µCi/ml), 10 mM 
ATP, 5 mM MgCl 2 , 200 µM CoA, 200 µM DTT, and 0.4% Triton 
X-100. The assay was initiated by addition of 5–10 µl of enzyme 
suspension (30–50 µg) from total or mitochondrial extracts from 
L6E9 myotubes. The reaction was carried out at 30°C for 5 min. 
Reactions were terminated with the addition of 1.25 ml of isopro-
pyl alcohol:heptane:H 2 SO 4 (40:10:1, v/v/v), 0.5 ml of water, and 
0.75 ml of heptane to facilitate organic phase separation. The 
aqueous phase was extracted three times with 0.75 ml of heptane 
to remove unreacted fatty acids, and the radioactivity was deter-
mined by liquid phase scintillation counting. 
 Immunoprecipitation 
 Immunoprecipitation studies were performed in L6E9 myo-
tubes and rat skeletal muscle. L6E9 cells were grown on 150 mm 
plates, differentiated, and transduced with the adenoviruses. Af-
ter transduction, cells were collected in PBS and homogenized 
with a douncer in 500   l of lysis buffer (50 mM Tris, pH 7.5, 150 
mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM EGTA, 1   M 
PMSF, 25   g/ml leupeptin, and 25   g/ml aprotinin) and centri-
fuged at 700  g for 10 min to remove nuclei, cell debris, and fl oating 
cells. For muscle studies, two soleus samples or one gastrocne-
mius sample were homogenized in 9 volumes of lysis buffer using 
a polytron. Homogenates were rotated for 1 h at 4°C in an orbital 
shaker and centrifuged at 5,000  g for 10 min at 4°C. After that, 
1,000 or 2,000   g of protein was immunoprecipitated with 5   g/
ml of either anti-FATP1 or anti-FAT/CD36 antibody. For immu-
noprecipitation studies in mitochondria, mitochondrial fractions 
were obtained as described above, 1% Triton X-100 was added to 
each preparation, and 150 or 300   g of each fraction was used. 
Immunoprecipitates were collected on protein A-Sepharose G 
beads, washed fi ve times in lysis buffer, resuspended, and incu-
bated for 5 min at 95°C in 1× SDS-PAGE sample buffer. Samples 
were resolved in 8% SDS-PAGE. A CPT1A-specifi c polyclonal 
antibody against amino acids 317–430 of the rat CPT1A ( 25 ) 
(1/6,000 dilution) was used for the detection of CPT1A protein 
in the immunoprecipitates from L6E9 myotubes. A CPT1B-
specifi c antibody against amino acids 259–760 of the rat CPT1B 
( 26 ) was used (1/1,000 dilution) for detection of CPT1B protein 
in the immunoprecipitates from rat skeletal muscle. 
 Immunofl uorescence 
 Cells grown on cover slips were fi xed for 15 min with 3% para-
formaldehyde in PBS and then rinsed three times with PBS and 
the assay, cells were washed in Krebs-Ringer bicarbonate HEPES 
buffer (KRBH buffer: 135 mM NaCl, 3.6 mM KCl, 0.5 mM 
NaH 2 PO 4 , 0.5 mM MgSO 4 , 1.5 mM CaCl 2 , 2 mM NaHCO 3 , and 
10 mM HEPES, pH 7.4) that contained 0.1% BSA, preincubated 
at 37°C for 30 min in KRBH 1% BSA and washed again in KRBH 
0.1% BSA. Cells were then incubated for 3 h at 37°C with fresh 
KRBH containing 2.5 mM glucose and 0.8 mM carnitine plus 
0.25 mM palmitate and 1   Ci/ml [1- 14 C]palmitate bound to 1% 
BSA. Oxidation measurements were performed by trapping the 
radioactive CO 2 in a parafi lm-sealed system. The reaction was 
stopped by the addition of 40% perchloric acid through a syringe 
that pierced the parafi lm. 
 Isolation of mitochondria from L6E9 cells and rat 
skeletal muscle 
 Mitochondria-enriched cell fractions from L6E9 myotubes 
were obtained as previously described ( 23 ) with some modifi ca-
tions. Briefl y, L6E9 cells were grown in 150 mm dishes, left to 
differentiate, and transduced as described above. Cells were 
scraped out and resuspended in 1 ml of solution A (100 mM KCl, 
5 mM MgSO 4 , 5 mM EDTA, 1 mM ATP, and 50 mM Tris-HCl, 
pH 7.4). Cells were homogenized using a glass homogenizer 
(20 strokes with both the loose and the tight pestle) and centri-
fuged at 2,000  g for 3 min at 4°C. The supernatant was centri-
fuged again at 16,000  g for 30 min at 4°C. The mitochondria-enriched 
pellet was resuspended in 50–100 µl of solution B (220 mM su-
crose, 70 mM mannitol, 1 mM EDTA, and 10 mM Tris-HCl, 
pH 7.4) and used for immunoprecipitation or palmitate oxida-
tion assays. The quality of mitochondria was assessed measuring 
the malonyl-CoA-resistant CPT1 activity, attributable basically to 
CPT2 activity inside the mitochondrion, allowing us to quantify 
broken mitochondria. According to this method, the integrity of 
mitochondria was higher than 80% (data not shown). 
 Mitochondria-enriched fractions from rat muscle were ob-
tained by differential centrifugation. Two soleus muscle samples 
or one gastrocnemius muscle sample from each animal were ho-
mogenized separately in 9 volumes of solution A using an omni-
mixer and then centrifuged at 1,000  g for 15 min. The pellet was 
homogenized and centrifuged at 600  g for 10 min. The resulting 
supernatant was centrifuged at 15,000  g for 15 min, and the pel-
let was washed twice in solution A and resuspended at 1 µl/mg 
tissue in solution B. 
 Measurement of palmitate and palmitoyl-CoA oxidation 
in isolated mitochondria 
 L6E9 cells were cultured in 150 mm dishes, differentiated, and 
transduced as described above. Mitochondria-enriched fractions 
were obtained and resuspended in solution B. Fatty acid oxida-
tion was measured as described elsewhere ( 12 ) with minor modi-
fi cations. For palmitate oxidation assays, 50 µl (150 µg) of 
mitochondria and 50 µl of a 2.5 mM 5:1 palmitate-BSA complex 
containing 10 µCi/ml [1- 14 C]palmitate (fi nal concentration: 0.25 
mM palmitate and 1 µCi/ml [1- 14 C]palmitate) were incubated 
for 1 h with agitation in 400 µl of pregassed (37°C for 15 min with 
5% CO 2 -95% O 2 ) modifi ed Krebs Ringer HEPES (MKRH) buffer 
(115 mM NaCl, 2.6 mM KCl, 1.2 mM KH 2 PO 4 , 10 mM NaHCO 3 , 
and 10 mM HEPES, pH 7.4) supplemented with 5 mM ATP, 
1 mM NAD + , 0.5 mM  L -carnitine, 0.1 mM CoA, 0.5 mM malate, and 
25   M cytochrome C (complete MKRH buffer). For palmitoyl-
CoA oxidation assays 50 µl (400 µg) of mitochondria and 50 µl of 
a 2.5 mM 5:1 palmitoyl-CoA-BSA complex containing 1 µCi/ml 
[1- 14 C]palmitoyl-CoA was added to the reaction mixture (fi nal 
concentration: 0.25 mM palmitoyl-CoA and 0.1 µCi/ml [1- 14 C]
palmitoyl-CoA) were incubated for 0.5 h with agitation in 400 µl 
of pregassed complete MKRH buffer. Oxidation measurements 
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0.36 ± 0.04 nmol palmitate/mg protein × h), and no increase 
was seen for PLs, DAG, or nonesterifi ed palmitate (NEPalm) 
(LacZ control values in nmol palmitate/mg protein × h: 
0.14 ± 0.01, 0.08 ± 0.01, and 0.033 ± 0.003 for PL, DAG, 
and NEPalm, respectively;  Fig. 2A ). L6E9 myotubes trans-
duced with Ad-FATP1 showed a 1.5-fold increase in palmi-
tate oxidation to CO 2 compared with Ad-LacZ-transduced 
myotubes (6.5 ± 0.27 nmol palmitate/mg protein × 3 h; 
 Fig. 2B ). We also examined the effect of FAT/CD36 over-
expression in L6E9 myotubes, a protein that has already been 
shown to have a role in fatty acid oxidation in muscle ( 12 ). 
Overexpression of FAT/CD36 (2-fold increase in protein 
levels;  Fig. 1B ) produced a 1.5- to 1.8-fold increase in palmi-
tate esterifi cation to TG, PL, DAG, and NEPalm ( Fig. 2A ) 
and a 1.5-fold increase in palmitate oxidation ( Fig. 2B ). 
 Effect of FATP1 overexpression on acyl-CoA 
synthetase activity 
 As FATP1 has acyl-CoA synthetase activity ( 13 ), we evalu-
ated whether the overexpression of FATP1 in L6E9 myotubes 
was followed by an increase in this activity. We determined 
the conversion of palmitate into palmitoyl-CoA in both total 
and mitochondria-enriched extracts. Acyl-CoA synthetase 
activity increased by 30% and 70% in total and mitochon-
drial extracts, respectively, in FATP1-overexpressing L6E9 
myotubes compared with LacZ control cells (control val-
ues: 2.99 ± 0.16 and 3.91 ± 0.37 nmol palmitoyl-CoA/mg 
protein × min in total and mitochondrial extracts, respec-
tively;  Fig. 2C ). 
 Effect of FATP1 on fatty acid oxidation in 
isolated mitochondria 
 To assess the role of FATP1 in fatty acid oxidation, we 
measured palmitate oxidation in mitochondria-enriched 
fractions. Palmitate oxidation to CO 2 increased 1.7-fold in 
mitochondria isolated from FATP1-overexpressing cells 
compared with Ad-LacZ infected cells (0.16 ± 0.009 nmol 
palmitate/mg protein × h;  Fig. 3A ). As a positive control, we 
also evaluated palmitate oxidation in CPT1-overexpressing 
cells. Overexpression of CPT1A (3-fold increase in protein 
subsequently incubated for 10 min in PBS containing 50 mM 
NH 4 Cl, for 10 min with PBS containing 20 mM glycine, and for 
10 min in PBS containing 0.1% triton X-100 and 0.05% colic 
acid. Cells were then washed three times in PBS 1× and for 30 
min in PBS containing 10% goat serum. Thereafter, cover slips 
were incubated with primary antibodies at 0.5–1.0 µg/ml anti-COI 
of complex IV (Molecular Probes) and revealed with fl uorochrom-
conjugated goat secondary antibodies (Texas Red). Cells were 
rinsed three times with PBS prior to mounting in medium for 
fl uorescence microscopy (Vectashield). Fluorescence images 
were obtained with a Leica TCS 4D confocal scanning laser mi-
croscope adapted to an inverted Leitz DMIRBE microscope and 
63× (numerical aperture 1.4 oil) Leitz Plan-Apo objectives. The 
light source was an argon/krypton laser (75 mW), with which 
optical sections (0.1 µm) were obtained. Qualitative analyses of 
colocalization were assessed using the plugin RGB Profi ler from 
the WCIF ImageJ software. A line was drawn arbitrarily over an 
area of interest and the plot presented the overlap of the staining 
of each laser (from distinct labeled proteins). Quantitative analy-
ses were performed by calculating Pearson’s correlation coeffi -
cient and Mander’s overlap coeffi cient, which are both described 
in the online manual for the WCIF ImageJ collection. In many 
forms of correlation analysis, the value for Pearson’s range from 
1 to   1. A value close to 1 does indicates reliable colocalization. 
The Mander’s overlap coeffi cient ranges from 1 to 0, with 1 being 
high colocalization and 0 being low. Having defi ned and elimi-
nated the background noise from the original picture, we used the 
plugin Intensity Correlation Analysis from WCIF ImageJ software. 
 Western blotting 
 Mitochondrial fractions were obtained by differential centrifu-
gation of muscle cell homogenates. Extracts were prepared by 
scraping L6E9 cell monolayers from 6 cm dishes into 700 µl of 
homogenization buffer consisting of 250 mM sucrose, 10 mM 
HEPES (pH 7.4), 1 mM EDTA, 1   M PMSF, 25   g/ml leupeptin, 
25   g/ml pepstatin A, and 25   g/ml aprotinin. Cells were homog-
enized with the aid of a 22G-syringe (15 times). The homogenates 
were centrifuged at 1,500  g for 10 min, and the supernatant was 
then centrifuged at 10,000  g for 10 min to obtain a pellet enriched 
in mitochondria and other organelles ( 27 ). All fractions were 
stored at   80°C, and an aliquot of the cell extracts was used for 
the measurement of protein concentration. Fifty micrograms of 
protein was resolved in 10% SDS-PAGE, and immunoblotting 
was performed with the corresponding antibody. 
 Statistical Analysis 
 Data are expressed as means ± SE. The signifi cance of differ-
ences was assessed by a one-way or two-way ANOVA followed by 
Newman-Keuls test for comparisons post hoc. Differences were 
considered signifi cant when  P < 0.05. 
 RESULTS 
 Effect of overexpression of FATP1 on lipid partitioning 
in L6E9 myotubes 
 Mouse FATP1 cDNA was delivered into L6E9 myotubes 
by adenovirus. FATP1 protein levels increased 2-fold in 
Ad-FATP1-transduced cells compared with control Ad-
LacZ-transduced cells ( Fig. 1A ). To assess the functionality 
of the overexpressed FATP1, we measured the incorpora-
tion of palmitate into lipids and oxidation in intact cells. 
FATP1 overexpression produced a 2-fold increase in the 
incorporation of palmitate into TGs (LacZ control value: 
 Fig.  1. Overexpression of FATP1, FAT/CD36, and CPT1A in 
L6E9 myotubes. L6E9 myotubes were transduced with Ad-FATP1, 
Ad-FAT/CD36, Ad-CPT1A, or Ad-LacZ as a control, and a Western 
blot using a specifi c antibody against FATP1 (A), FAT/CD36 (B), 
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overexpessing cells compared with Ad-LacZ control cells 
(36.1 ± 1.5 nmol palmitate/mg protein × h;  Fig. 3B ). When 
mitochondria were incubated with etomoxir, an irrevers-
ible inhibitor of CPT1, the increments in fatty acid oxida-
tion in FATP1- and FAT/CD36-overexpressing cells were 
blunted, confi rming that CPT1 activity is necessary for 
fatty acid import into mitochondria ( Fig. 3A, B ). We also 
determined the ratio of incomplete (ASPs) versus com-
plete (CO 2 ) oxidation as a measure of mitochondrial fatty 
acid oxidation effi ciency. The overexpression of CPT1A, 
FATP1, and FAT/CD36 produced a 30–40% decrease in 
the ratio ASP/CO 2 . Importantly, the cooverexpression of 
CPT1A together with FATP1 or FAT/CD36 produced a 
50–60% decrease in this ratio ( Fig. 3C ), indicating that the 
overexpression of these proteins increased fatty acid oxi-
dation effi ciency. 
 To assess whether the role of FATP1 in the increase in 
mitochondrial fatty acid oxidation was due to its acyl-CoA 
synthetase activity, providing the substrate for CPT1, we 
levels;  Fig. 1C ), the endogenous CPT1 isoform expressed 
in these cells ( 22 ), produced a 2.6-fold increase in mito-
chondrial palmitate oxidation to CO 2 . Moreover, overex-
pression of FAT/CD36 also increased palmitate oxidation 
to CO 2 by 2.0-fold. To further evaluate the role of FATP1 
in fatty acid oxidation, we overexpressed both FATP1 and 
CPT1 proteins together. The overexpression of CPT1A 
and FATP1 enhanced fatty acid oxidation to CO 2 by 4.7-
fold, showing an additive effect ( Fig. 3A ). Similarly, coover-
expression of CPT1A and FAT/CD36 also produced an 
additive effect on palmitate oxidation to CO 2 (4.1-fold in-
crease). Palmitate oxidation to ASPs, essentially consisting 
of acyl-carnitines, Krebs cycle intermediates, and acetyl-
CoA, was increased from 1.4- to 1.8-fold in CPT1A-, FAT/
CD36-, FATP1-, CPT1A+FAT/CD36-, and CPT1A+FATP1-
 Fig.  2. Effect of FATP1 overexpression on palmitate metabolism 
and acyl-CoA synthetase activity. A: Palmitate incorporation into 
complex lipids. L6E9 cells that were infected with Ad-LacZ, Ad-
FATP1, and Ad-FAT/CD36 were incubated for 16 h in serum-free 
medium containing 1   Ci/ml [1- 14 C]palmitic acid and 0.25 mM 
unlabeled palmitate complexed to 1% (w/v) BSA. Fatty acid incor-
poration into TGs, DAG, PLs, and NEPalm was assessed using TLC 
after lipid extraction. B: Fatty acid oxidation. Cells were infected 
with Ad-LacZ, Ad-FATP1, or Ad-FAT/CD36, and palmitate oxida-
tion to CO 2 was measured for 3 h. C: Acyl-CoA synthetase activity 
was measured in both total and mitochondrial extracts coming 
from L6E9 myotubes transduced with Ad-LacZ or Ad-FATP1. Data 
are the mean ± SE of fi ve experiments performed in triplicate. * P < 
0.01 versus Ad-LacZ; ** P < 0.001 versus Ad-LacZ. 
 Fig.  3. Palmitate oxidation in mitochondrial fractions. Mito-
chondrial fractions that were obtained from cells infected with Ad-
LacZ, Ad-FATP1, Ad-CPT1A, or Ad-FAT/CD36 were incubated for 
1 h with agitation in 400 µl of pregassed complete MKRH buffer 
and 50 µl of a 2.5 mM 5:1 palmitate-BSA complex containing 10 
µCi/ml [1- 14 C]palmitic acid, and palmitate oxidation to CO 2 (A) 
and to ASPs (B) was measured. The ratio of ASPs/CO 2 was also 
calculated (C). Data are the mean ± SE of fi ve experiments per-
formed in duplicate. * P < 0.01 versus  Ad-LacZ, ** P < 0.001 versus 
Ad-LacZ,  & P < 0.001 versus the overexpression of only one protein 
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FATP1 or FAT/CD36 ( Fig. 5 ). Indeed, the overexpression 
of FATP1, FAT/CD36, or CPT1 only affected the expres-
sion of the protein that had been overexpressed but not 
the other proteins studied ( Fig. 5 ). 
 Cellular localization of FATP1 
 The increase in fatty acid oxidation in isolated mito-
chondria from FATP1-overexpressing cells suggested that 
FATP1 could be localized in the mitochondrion. There-
fore, L6E9 myotubes were transfected with a plasmid that 
expressed an N-terminal FATP1-GFP fusion protein, and a 
Western blot against GFP or FATP1 was performed. We 
detected a band corresponding to the FATP1-GFP fusion 
protein (using the GFP antibody) and the endogenous 
FATP1 protein (using FATP1 antibody) in the 10,000  g mi-
tochondrial pellet but not in the 10,000  g supernatant 
( Fig. 6A ). Indeed, this distribution was similar to that of 
the mitochondrial marker protein porin. The same result 
was obtained for endogenous FAT/CD36 protein and 
overexpressed FAT/CD36-GFP fusion protein, which is 
consistent with the mitochondrial localization of FAT/
CD36 protein in muscle ( Fig. 6A ). 
 To confi rm that FATP1 is localized in mitochondria, we 
used immunocytochemistry in L6E9 myotubes transfected 
with the FATP1-GFP construct. As a marker of the mito-
chondrial network, we used subunit I of cytochrome c oxi-
dase (COI), an enzyme located in the mitochondrial inner 
membrane that forms part of Complex IV of the respira-
tory chain ( 29 ). We showed that COI protein has a tubular 
mitochondrial pattern in L6E9 myotubes. The merging of 
FATP1-GFP with the mitochondrial marker COI revealed 
a partial overlap of these two proteins, and imaging analy-
sis indicated a substantial colocalization of both pro-
teins (Pearson coeffi cient of colocalization was 0.537, and 
Mander’s Overlap coeffi cient was 0.723), confi rming the 
mitochondrial localization of FATP1-GFP protein ( Fig. 6B ). 
Qualitative analyses of colocalization were assessed using 
the plugin RGB Profi ler from the WCIF ImageJ software. 
An arbitrary line was drawn over an area of interest, and 
the plot presents the overlap of staining of each laser (from 
distinct labeled proteins;  Fig. 6C ). 
measured palmitoyl-CoA oxidation to CO 2 and ASPs in iso-
lated mitochondria, where palmitoyl-CoA is oxidized in the 
absence of acyl-CoA synthetase activity. The overexpres-
sion of either CPT1 or FATP1 alone produced an increase 
in fatty acid oxidation to CO 2 compared with LacZ control 
cells (2.20 ± 0.11 nmol palmitoyl-CoA/mg protein × h), 
which was additive when both proteins were overexpressed 
together ( Fig. 4A ). However, no signifi cant difference was 
observed in palmitoyl-CoA oxidation to ASPs in FATP1-
overexpressing cells compared with LacZ control cells 
(27.6 ± 0.37 nmol palmitoyl-CoA/mg protein × h;  Fig. 4B ). 
 Increased fatty acid uptake has been shown to increase 
transcription of CPT1 via a peroxisome proliferator- 
activated receptor (PPAR)-dependent pathway ( 28 ). To 
assess the possibility that the increase in fatty acid oxidation 
was due to increased expression of CPT1 in cells overex-
pressing FATP1 as a consequence of an increased infl ux of 
fatty acids, we performed a Western blot for CPT1 in L6E9 
myotubes. CPT1 protein levels were increased in cells 
overexpressing CPT1 but not in those cells overexpressing 
 Fig.  5. Protein expression levels of CPT1A, FATP1, and FAT/
CD36 in L6E9 myotubes. Western blot for CPT1A, FATP1, and 
FAT/CD36 proteins was performed in 50 µg of mitochondrial frac-
tions obtained from cells infected with Ad-LacZ, Ad-CPT1A, Ad-
FATP1, and Ad-FAT/CD36. Western blot against porin was used as 
a mitochondrial loading control. 
 Fig.  4. Palmitoyl-CoA oxidation in mitochondrial fractions. Mito-
chondrial fractions that were obtained from cells infected with 
Ad-LacZ, Ad-FATP1, or Ad-CPT1A were incubated for 0.5 h with 
agitation in 400 µl of pregassed complete MKRH buffer and 50 µl 
of a 2.5 mM 5:1 palmitoyl-CoA-BSA complex containing 1 µCi/ml 
[1- 14 C]palmitoyl-CoA and palmitoyl-CoA, and oxidation to CO 2 
(A) and to ASPs (B) was measured. Data are the mean ± SE of three 
experiments performed in duplicate. * P < 0.01 versus Ad-LacZ; 
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were overexpressed ( Fig. 7A, B ). Importantly, to confi rm 
that FATP1 and CPT1 colocalize in mitochondria, we 
performed immunoprecipitation assays in vivo using rat 
skeletal muscle. FATP1 and CPT1 coimmunoprecipi-
tated in both total extracts and in isolated mitochondrial 
fractions coming from gastrocnemius and soleus muscles 
( Fig. 7D ). 
 DISCUSSION 
 Regulation of fatty acid oxidation in skeletal muscle has 
been the object of many studies attempting to explain the 
disconnection between malonyl-CoA levels measured in 
muscle and the IC 50 for the muscle isoform of CPT1. In a 
recent study, we showed that overexpression of CPT1A in 
L6E9 myotubes enhanced CPT1 activity up to 15-fold, 
whereas fatty acid oxidation did not increase more than 
2-fold, even when a mutant form of CPT1A insensitive to 
malonyl-CoA was overexpressed ( 22 ). These data indicate 
that other factors independent of the CPT1/malonyl-CoA 
interaction could be involved in the control of fatty acid 
oxidation in muscle. Furthermore, proteins other than 
CPT1 have recently been implicated in fatty acid import 
into mitochondria in muscle, such as FAT/CD36 ( 12 ) and 
UCP3 ( 31 ). FAT/CD36 translocates to the mitochondria 
during muscle contraction, increasing fatty acid oxidation. 
Furthermore, a null mutation in skeletal muscle FAT/
CD36 reveals that palmitate metabolism is markedly down-
regulated under insulin- and AICAR-stimulated condi-
tions. This indicates its critical role in fatty acid esterifi cation 
and oxidation and points to another level of regulation in 
 FAPT1 and CPT1 interact in mitochondria 
 If FATP1 is localized in mitochondria and enhances 
fatty acid oxidation, FATP1 and CPT1 could interact in 
the mitochondria. To assess this possibility, we performed 
coimmunoprecipitation assays. FATP1 was immunopre-
cipitated from total lysates of cells infected with Ad-LacZ, 
Ad-FAPT1, Ad-CPT1A, or Ad-FATP1 + Ad-CPT1A, and these 
immunoprecipitates were then subjected to a Western 
blot analysis using a CPT1A-specifi c antibody. We de-
tected a band corresponding to CPT1 in immunoprecipi-
tates obtained from CPT1A-overexpressing cells, showing 
an interaction between FATP1 and CPT1 ( Fig. 7A ). To 
confi rm that the two proteins interact in mitochondria, 
we also performed immunoprecipitation assays using mi-
tochondrial fractions from these cells. As shown for the 
case of total lysates, FATP1 and CPT1A coimmunopre-
cipitated in these fractions ( Fig. 7B ). Since we did not see 
coimmunoprecipitation of FATP1 and CPT1A in control 
LacZ cells, to rule out the possibility that the coimmu-
noprecipitation could be an artifact of the overexpres-
sion system, we performed immunoprecipitation assays 
using a greater amount of either total extracts or mito-
chondrial extracts. Using this approach, we showed that 
endogenous FATP1 and CPT1A coimmunoprecipitated 
in both total and mitochondria-enriched extracts in con-
trol L6E9 myotubes ( Fig. 7C ). FAT/CD36 has been shown 
to coimmunoprecipitate with CPT1 in human skeletal 
muscle ( 30 ). We performed immunoprecipitation assays 
in our system, which overexpresses FAT/CD36, and found 
that the two proteins also coimmunoprecipitated in both 
total and mitochondrial extracts when both proteins 
 Fig.  6. FATP1 localizes in mitochondria in L6E9 
myotubes. A: L6E9 myoblasts were transfected with 
pFATP1-GFP or pFAT/CD36-GFP and induced to dif-
ferentiate. Western blot analyses were performed 48 
h posttransfection on total cell extracts (TE) (35 µg 
protein), mitochondrial enriched fractions (mit) (35 
µg protein) after centrifugation at 1,500  g and 10,000 
 g , or the supernatant (Sup.) of the 10,000  g pellet (35 
µg) and membranes hybridized with antibodies 
against FAT/CD36, FATP1, GFP, or porin as stated. B: 
Colocalization analysis of the mitochondrial marker 
COI and FATP1-GFP. L6E9 cells were transfected with 
pFATP1-GFP and studied 48 h posttransfection. a: Im-
age of the FATP1-GFP protein observed under a con-
focal microscope. b: Image of mitochondrial network 
by staining with antibodies against COI. c: Colocaliza-
tion of the signal of GFP and COI. C: Qualitative 
analyses of colocalization were assessed using the 
plugin RGB Profi ler from the WCIF ImageJ software. 
A line was drawn arbitrarily over an area of interest, 
and the plot presents the overlap of the intensity of 
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increased ( 18 ). This discrepancy could be due to differences 
in the model studied and the method used: in this study, 
palmitate oxidation was measured in the presence of 2.5 
mM glucose, whereas in the previous study, palmitate oxi-
dation was measured in human skeletal muscle cells and 
in the absence of glucose. The increase in fatty acid oxida-
tion in FATP1-overexpressing L6E9 myotubes in our study 
is consistent with the increase shown for transgenic mice 
overexpressing FATP1 in heart ( 17 ). However, the TG levels 
were not increased in the heart of transgenic mice. 
 To assess whether the increase in fatty acid oxidation is 
a result of an increase in fatty acid uptake at the plasma 
membrane or due to a mitochondrial role of FATP1, we 
isolated mitochondrial-enriched fractions and measured 
palmitate oxidation. We found that FATP1 overexpression 
increased mitochondrial fatty acid oxidation, as did the 
overexpression of CPT1A, the endogenous CPT1 isoform 
expressed in these cells ( 22 ). Importantly, the overexpres-
sion of both proteins together produced an additive ef-
fect, indicating that FATP1 and CPT1 collaborate in these 
fatty acid oxidation ( 32 ). In these FAT/CD36 KO mice, 
there was an upregulation of FATP1 and FATP4 in the so-
leus muscle. This upregulation failed to normalize fatty 
acid oxidation, but it indicates that other proteins like 
FATP1 could collaborate in the maintenance of fatty acid 
metabolism. In search for a novel regulator of fatty acid 
metabolism in muscle, in this study, we demonstrate for 
the fi rst time that FATP1, a fatty acid transport protein, is 
involved in mitochondrial fatty acid oxidation. 
 Overexpression of FATP1 in L6E9 myotubes using ade-
novirus increased acyl-CoA synthetase activity and fatty 
acid incorporation into TGs, but not into other lipid spe-
cies such as PL, DAG, or NEPalm. These results are consis-
tent with other in vitro studies in 293 cells showing that 
fatty acids taken up by FATP1 are preferentially channeled 
into TG synthesis ( 33 ). Moreover, FATP1 overexpression 
increased fatty acid oxidation in intact myotubes. This 
result contrasts with the effect of FATP1 overexpression 
in human skeletal muscle cells, where palmitate incor-
poration into TG, but not fatty acid oxidation, was also 
 Fig.  7. Coimmunoprecipitation of FATP1 and CPT1. L6E9 myotubes were transduced with Ad-LacZ, Ad-
CPT1A, Ad-FATP1, and Ad-FAT/CD36, and FATP1 or FAT/CD36 proteins were immunoprecipitated using 
specifi c antibodies in either total extracts (1,000 µg) (A) or mitochondrial extracts (150 µg) (B), and CPT1A 
protein was detected in these immunoprecipitates by Western blot. C: FATP1 protein was immunoprecipi-
tated in either total extracts (2,000 µg) or mitochondrial-enriched extracts (300 µg) from L6E9 myotubes, 
and CPT1A protein was detected by Western blot. D: FATP1 protein was immunoprecipitated in either total 
extracts (1,000 µg) or mitochondria-enriched extracts (150 µg) from both gastrocnemius and soleus mus-
cles, and CPT1B protein was detected by Western blot using a specifi c antibody. Total expression of CPT1B 
in 50 µg of total and mitochondrial extracts is also shown (Input). A negative control with an unspecifi c 
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both proteins indicate that these two proteins may interact 
in the mitochondrion. We show that both proteins coimmu-
noprecipitated both in total extracts and in mitochondrial 
extracts, strongly supporting the hypothesis that FATP1 and 
CPT1 interact in mitochondria. Importantly, using rat skeletal 
muscle, we also showed that FATP1 and CPT1 coimmuno-
precipitated both in total extracts and in mitochondria-
enriched fractions, indicating that the interaction between 
FATP1 and CPT1 also occurs in skeletal muscle in vivo. 
Moreover, this coimmunoprecipitation was higher in soleus 
than in gastrocnemius muscle. This indicates that in oxi-
dative muscle, which uses primary fatty acids as an energy 
source, the interaction between FATP1 and CPT1 could be 
higher than in glycolytic muscles. Furthermore, FATP1 ex-
pression in rat oxidative muscle (soleus) is approximately 
twice that in glycolytic (gastrocnemius) muscle ( 37 ). Our im-
munoprecipitation assays in L6E9 myotubes and rat skeletal 
muscle show that FATP1 and CPT1 interact in basal condi-
tions, suggesting that FATP1 could be constitutively present 
in mitochondria. However, some hormonal or physiological 
factors that induce fatty acid oxidation, such as exercise, 
could also induce the presence of FATP1 in mitochondria. 
Future studies are needed to examine this possibility. 
 FATP1 is an integral membrane protein with at least 
one transmembrane and multiple membrane-associated 
domains ( 35 ). It contains an AMP-binding motif that is es-
sential for transport function ( 38 ). FATP1 has acyl-CoA 
synthetase activity, suggesting that fatty acid uptake cata-
lyzed by FATP1 is linked to the esterifi cation of these fatty 
acids with CoA ( 13 ). Moreover, FATP1 was shown to het-
erooligomerize with the LCFA-CoA syntethase ACSL1 in 
differentiated 3T3-L1 adipocytes ( 39 ). Given all the above 
observations, it could be hypothesized that FATP1 could 
act as a long-chain acyl-CoA synthetase in mitochondria to 
activate LCFAs, which CPT1 can then use as a substrate. 
However, interestingly, although acyl-CoA synthetase ac-
tivity is increased in mitochondrial fractions from FATP1-
overexpressing L6E9 myotubes, we show that mitochondrial 
palmitoyl-CoA oxidation to CO 2 is also increased in these 
fractions, as is the oxidation of palmitate, suggesting a role 
for FATP1 in mitochondrial fatty acid oxidation indepen-
dent of its acyl-CoA synthetase activity. 
 In this study, we have also analyzed the effect of overex-
pression of FAT/CD36 in L6E9 myotubes. This has been 
described as a new protein involved in mitochondrial fatty 
acid oxidation under stimulated conditions ( 12 ). Thus, 
the presence of FAT/CD36 in mitochondria is induced by 
exercise or contraction ( 12 ). However, FAT/CD36 KO 
mice have normal basal mitochondrial fatty acid oxidation 
despite the absence of FAT/CD36 protein ( 40 ). These 
results suggest that FAT/CD36 could have a role in mito-
chondrial fatty acid oxidation only under certain condi-
tions of increased requirements for fatty acid oxidation, 
such as during exercise or muscle contraction. Moreover, 
FAT/CD36 has been shown to translocate from intracel-
lular vesicles to the plasma membrane in response to insulin 
( 41 ). In this study, we have demonstrated that overex-
pression of FAT/CD36 enhances fatty acid oxidation, in 
agreement with the increase in fatty acid oxidation shown 
cells for mitochondrial fatty acid oxidation. It has been 
suggested than when the rate of mitochondrial   -oxidation 
is increased and exceeds fl ux through the tricarboxylic 
acid cycle and electron transport chain, incomplete fatty 
acid oxidation occurs, leading to intramitochondrial me-
tabolite accumulation, mitochondrial stress, and cellular 
insulin resistance ( 34 ). In our study, FATP1 overexpres-
sion produced a higher increase in complete than in in-
complete fatty acid oxidation, indicating that the effect of 
this protein on fatty acid oxidation does not involve the 
accumulation of intermediary species of fatty acid oxida-
tion. Hence, FATP1 overexpression increased the effi ciency 
of the mitochondria to oxidize fatty acids, as indicated by 
the diminished ratio incomplete/complete fatty acid oxi-
dation. This effect was also seen in cells overexpressing 
CPT1A, especially when both FATP1 and CPT1A were 
cooverexpressed, showing a higher coupling of mitochon-
drial fatty acid uptake and oxidation. Interestingly, the use 
of etomoxir showed that the control of mitochondrial fatty 
acid uptake was dominated by CPT1, and the overexpres-
sion of FATP1 had no effect when CPT1 was inhibited. 
This indicates that FATP1 contributes to fatty acid oxida-
tion by collaborating with CPT1, but not by controlling 
the entry of fatty acids to the mitochondria. 
 If FATP1 has a role in mitochondrial fatty acid oxida-
tion, it might be localized in mitochondria. To examine 
this possibility, we used different techniques. Western blot 
analysis demonstrated that the protein was present in 
mitochondrial fractions but not in cytosolic fractions. 
Moreover, using immunocytochemistry, we showed both 
qualitatively and quantitatively that FATP1-GFP protein 
localized partially in structures that were also positive for 
the mitochondrial protein COI, indicating that FATP1 is 
partially localized in mitochondria in L6E9 myotubes. We 
used GFP fl uorescence since the FATP1 antibodies were 
unsuitable for immunocytochemistry studies. Although the 
fusion with GFP could affect the localization of the pro-
tein, we do not believe this is the case. In the Western blot 
experiments, the FATP1-GFP and the endogenous protein 
showed the same distribution pattern of localization after 
the cellular fractionation, and another report ( 35 ) showed 
that the N-terminal GFP-tagged FATP1 protein retained 
the ability to bind to membranes. In our study, not all the 
FATP1 colocalized with the mitochondrial marker COI. It 
has been described that FATP1 can also localize in the en-
doplasmic reticulum (ER) ( 35 ). Given the reticular pat-
tern of GFP fl uorescence that we observed in L6E9 cells, 
we cannot rule out the possibility that a portion of FATP1-
GFP could also localize in the ER. Furthermore, in a previ-
ous study in human myotubes, overexpressed FATP1-GFP 
also showed a cytosolic reticular pattern, but colocaliza-
tion studies with a mitochondrial or ER marker were not 
performed ( 18 ). Moreover, recent data from our group 
demonstrated that FATP1 also localizes in mitochondria in 
human and C2C12 muscle cells ( 36 ), and in adipocytes, 70% 
of FATP1 localizes in cell membrane fraction and approxi-
mately 10% in the nuclear-mitochondrial fraction ( 16 ). 
 The additive effect of FATP1 and CPT1 overexpression in 
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in contracting muscle in transgenic mice overexpressing 
FAT/CD36 ( 42 ). Furthermore, FAT/CD36 coimmunopre-
cipitated with CPT1 in L6E9 myotubes, and its overexpres-
sion increased mitochondrial fatty acid oxidation and 
mitochondrial fatty acid oxidation effi ciency, showing an 
additive effect when cooverexpressed with CPT1. It has 
already been shown that FAT/CD36 translocates to the mi-
tochondrial membrane in response to exercise, increasing 
the ability of mitochondria to oxidize palmitate, both in 
rats and in humans ( 12, 43 ). Moreover, FAT/CD36 coim-
munoprecipitates with CPT1, and this correlates with 
the level of fat oxidation in skeletal muscle ( 30 ). Thus, our 
results in L6E9 myotubes are in agreement with these 
previous data and validate our model of study. Therefore, 
according to our data, FATP1 enhances fatty acid oxida-
tion similar to FAT/CD36, suggesting that such effect may 
be due to fatty acid recruitment at mitochondria by either 
fatty acid binding protein. However, in a recent study, we 
have shown that FATP1, unlike FAT/CD36, stimulates the 
pyruvate dehydrogenase complex activity and glucose oxi-
dation in cultured myotubes ( 36 ), indicating that FATP1 
exerts differential effects on mitochondrial metabolism. 
 In summary, we demonstrate for the fi rst time that 
FATP1 has a role in mitochondrial fatty acid oxidation in 
collaboration with CPT1. The exact mechanism of this in-
teraction and its regulation remain to be resolved. How-
ever, the data presented here reveal a new protein involved 
in mitochondrial oxidation of fatty acids and could help us 
to understand the complex regulation of fatty acid oxida-
tion in skeletal muscle.  
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